We are focused on the treatment of hemophilia using our high potency coagulation factors that promote blood clotting. A clinical trial of our Factor IX candidate in individuals with hemophilia B was initiated in June of 2017. A Phase 2 of a Phase 2/3 clinical trial of our Factor VIIa candidate in individuals with hemophilia A or B with inhibitors was initiated in January of 2018.
Next Generation Hemostasis Programs
*(formerly known as CB 813d)